4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001209191-21-034191
Chief R&D Officer sold 31,111 shares at $18.30 ($569,331)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Zalevsky Jonathan Chief R&D Officer | 2021-05-17 | Sale | −31,111 | $18.30 | $569,331 | 235,065 | D |
| Open-market sales · 31,111 sh · avg $18.30 · $569,331 | |||||||
Loading xslF345X03/doc4.xml…